Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 06 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated